Regencell Bioscience Holdings Limited RGC
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.28M | 4.55M | 2.82M | 3.12M | 3.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.13M | 5.45M | 3.77M | 4.09M | 4.40M |
| Operating Income | -7.13M | -5.45M | -3.77M | -4.09M | -4.40M |
| Income Before Tax | -7.05M | -5.32M | -3.58M | -3.81M | -4.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.05 | -5.32 | -3.58 | -3.81 | -4.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -28.90K | -57.80K |
| Net Income | -7.05M | -5.32M | -3.58M | -3.84M | -4.09M |
| EBIT | -7.13M | -5.45M | -3.77M | -4.09M | -4.40M |
| EBITDA | -7.00M | -5.31M | -3.62M | -3.88M | -4.20M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | 0.00 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | 0.00 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B |
| Average Diluted Shares Outstanding | 1.98B | 1.98B | 1.98B | 1.98B | 1.98B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |